uniQure reports Q3 EPS ($1.38), consensus (76c)

Reports Q3 revenue $3.7M, consensus $4.46M. “The third quarter of 2025 marked a defining moment for uniQure (QURE) as we presented our topline three-year data of AMT-130, an investigational gene therapy for Huntington’s disease, that demonstrated statistically significant slowing of disease progression,” said Matt Kapusta, chief executive officer of uniQure. “While the recent FDA feedback was unexpected and has introduced uncertainty in the timing of our BLA submission, we strongly believe that AMT-130 has the potential to bring substantial benefit for patients with Huntington’s disease. We are fully committed to working with the FDA to determine the most expeditious path forward to rapidly bring AMT-130 to patients and their families in the U.S.”